Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) have received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $54.25.

Several research analysts recently commented on the company. Barclays increased their price target on Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Citigroup cut their price objective on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They set an “outperform” rating and a $42.00 target price on the stock. Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price target for the company in a research note on Monday, December 2nd. Finally, Robert W. Baird lowered their price objective on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research note on Thursday, November 7th.

Tandem Diabetes Care Trading Up 0.7 %

Tandem Diabetes Care stock opened at $33.59 on Thursday. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -17.40 and a beta of 1.32. The firm has a 50-day moving average of $35.44 and a 200-day moving average of $36.64. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care has a one year low of $25.78 and a one year high of $53.69.

Institutional Trading of Tandem Diabetes Care

Hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System increased its position in Tandem Diabetes Care by 1.9% during the 4th quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company’s stock worth $683,000 after buying an additional 362 shares during the period. Bank of Montreal Can boosted its stake in shares of Tandem Diabetes Care by 4.3% in the fourth quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company’s stock valued at $360,000 after buying an additional 409 shares during the period. Summit Investment Advisors Inc. increased its holdings in Tandem Diabetes Care by 8.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,870 shares of the medical device company’s stock valued at $247,000 after buying an additional 525 shares during the period. Assetmark Inc. raised its position in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock valued at $44,000 after buying an additional 535 shares in the last quarter. Finally, AlphaQuest LLC lifted its holdings in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after acquiring an additional 541 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.